Skip to Content

Optimizing PARP Inhibitor Therapy for Ovarian Cancer

Join Mansoor Raza Mirza as he delves into the field of second-line PARP inhibitor therapy in ovarian cancer. In this MEDtalk, he highlights the critical considerations for identifying patients who can benefit most from PARP inhibitors during relapse. He also elaborates on the significance of timing, the pivotal role of BRCAmut and HR-deficient populations, and the insights from the ENGOT-OV16/NOVA study that may redefine treatment strategies.

Mansoor Raza Mirza

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top